AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
BioXcel Therapeutics' BXCL501 Phase 3 Trial Success Supports Suggested Label Expansion for IGALMI in 2026
ByAinvest
Wednesday, Aug 27, 2025 10:51 pm ET1min read
BioXcel Therapeutics announced its SERENITY Phase 3 trial for BXCL501 met its primary endpoint, demonstrating safety and tolerability for treating agitation in bipolar disorder and schizophrenia patients at home. This successful trial supports the planned sNDA submission for IGALMI label expansion in early 2026, potentially addressing a significant unmet need in the at-home treatment market. The company's stock is rated Underperform by TipRanks' AI Analyst, Spark, due to substantial financial instability, including ongoing losses, high debt, and negative cash flows.
BioXcel Therapeutics, Inc. (Nasdaq: BTAI) announced today that its SERENITY At-Home Pivotal Phase 3 trial evaluating the safety of BXCL501 for the acute treatment of agitation associated with bipolar disorders or schizophrenia has met its primary endpoint. The trial, which evaluated the use of BXCL501 in an at-home setting, demonstrated that the 120 mcg dose of BXCL501 was well-tolerated and met the primary objective of being safe for patients with episodes of agitation [1].The SERENITY At-Home trial involved over 2,600 episodes of agitation, with no discontinuations due to tolerability in the BXCL501 group. The trial's success underscores the potential to address a significant unmet medical need, as there are currently no FDA-approved therapies for at-home agitation treatment [2].
Following the positive results, BioXcel plans to submit a supplemental New Drug Application (sNDA) in Q1 2026 to expand BXCL501's use to outpatient settings. The company aims to provide patients with access to IGALMI® in the home setting, potentially reducing healthcare costs and improving patient safety [1].
However, the company's stock is rated Underperform by TipRanks' AI Analyst, Spark, due to substantial financial instability, including ongoing losses, high debt, and negative cash flows [3].
References:
[1] https://www.ainvest.com/news/bioxcel-therapeutics-shares-rise-16-03-premarket-topline-results-serenity-home-pivotal-phase-3-trial-2508/
[2] https://www.quiverquant.com/news/BioXcel+Therapeutics+Reports+Successful+Results+from+SERENITY+At-Home+Trial+for+BXCL501+as+At-Home+Treatment+for+Agitation+in+Bipolar+Disorders+and+Schizophrenia
[3] https://www.tipranks.com/analysts/bioxcel-therapeutics-inc-btai
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet